Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brazil Needs Better Orphan Drug Policies, Says Alexion

Executive Summary

Strengthening Brazil’s policy on orphan drugs would help stem the number of court cases brought by patients to access medicines, says Alexion.

You may also be interested in...



Brazil: Spending On Meds Acquired Through Law Suits Rockets

Brazilian health ministry spending on medicines and treatment supplies acquired by patients taking legal action through the courts has rocketed from R$70m ($22.3) in 2008 to more than R$1bn ($317.9) in 2015, according to an audit by Brazil’s General Accounting Office (TCU).

South American Pricing Coalition Sets Sights On Alexion’s Soliris and Monoclonal Antibodies

A South American pricing coalition that includes Brazil, Venezuela and Argentina has announced plans to buy high-cost drugs, such as eculizumab (Alexion’s Soliris).

Voluntary EU Joint Clinical Assessments ‘Risk Access To Medicines’

Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.

Topics

Related Companies

UsernamePublicRestriction

Register

PS121590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel